Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are o...

Description complète

Détails bibliographiques

Auteurs principaux:	Sabine Schmid, MD, Lisa Holer, MSc, Katrin Gysel, MSc, Kira-Lee Koster, MD, Sacha I. Rothschild, MD, Laura A. Boos, MD, Lorenz Frehner, MD, Sabine Cardoso Almeida, MD, Christian Britschgi, MD, PhD, Yannis Metaxas, MD, Michael Mark, MD, Patrizia Froesch, MD, Wolf-Dieter Janthur, MD, Anna Allemann, MD, Christine Waibel, MD, Catherine Von der Mühll-Schill, MD, Martin Früh, MD, Laetitia A. Mauti, MD, PhD
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2024-12-01
Collection:	JTO Clinical and Research Reports
Sujets:	Malignant pleural mesothelioma Ipilimumab Nivolumab Real-world Outcome
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S266636432400105X
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!